Results 121 to 130 of about 10,090 (144)

Dolutegravir/dolutegravir/lamivudine/tenofovir/rifampicin

Reactions Weekly, 2021
openaire   +1 more source

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Lancet, The, 2021
Shahin Lockman, Lynda Stranix-Chibanda, Lee Fairlie   +2 more
exaly  

Dolutegravir/abacavir/dolutegravir/lamivudine

Reactions Weekly, 2018
openaire   +1 more source

Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV

New England Journal of Medicine, 2021
Stephen Ian Walimbwa, Barbara Castelnuovo, Agnes N Kiragga   +2 more
exaly  

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

New England Journal of Medicine, 2021
Anna Turkova, Tim R Cressey, Moherndran Archary   +2 more
exaly  

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Clinical Infectious Diseases, 2023
Chien-yu Cheng, Stephen Taylor
exaly  

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Lancet, The, 2018
Francesco Castelli, Michael Aboud
exaly  

Dolutegravir

Reactions Weekly
  +5 more sources

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Lancet, The, 2013
Andrey Shuldyakov, Carlos Brites, Jaime F Andrade-Villanueva   +2 more
exaly  

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Lancet, The, 2013
Carlo Torti, Chloe Orkin, Mark Bloch
exaly